Perspectives of CD44 targeting therapies

Archives of Toxicology

Volumn 89, Issue 1, 2015, Pages 3-14

  Orian Rousseau, V ^a   Ponta, H ^b  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^b AMCURE GMBH   (Germany)

Author keywords

CD44; Hyaluronan; Receptor tyrosine kinases; Therapy

Indexed keywords

APTAMER; CD44V6 ANTIGEN; HERMES ANTIGEN; MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT; HYALURONIC ACID;

CANCER STEM CELL; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ANIMAL; APOPTOSIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEAD AND NECK TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; APOPTOSIS; GENE EXPRESSION REGULATION; HEAD AND NECK NEOPLASMS; HUMANS; HYALURONIC ACID; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84935138318     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1424-2     Document Type: Review

References (127)

1. Ahrens T, Sleeman JP, Schempp CM et al (2001) Soluble CD44 inhibits melanoma tumor growth by blocking cell surface CD44 binding to hyaluronic acid. Oncogene 20(26):3399–3408
2. Akima K, Ito H, Iwata Y et al (1996) Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity. J Drug Target 4(1):1–8. doi:10.3109/10611869609046255
3. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61(7):1303–1313
4. Avigdor A, Goichberg P, Shivtiel S et al (2004) CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 103(8):2981–2989
5. Bartolazzi A, Peach R, Aruffo A, Stamenkovic I (1994) Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med 180(1):53–66
6. Bellocq NC, Pun SH, Jensen GS, Davis ME (2003) Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 14(6):1122–1132. doi:10.1021/bc034125f
7. Bennett KL, Jackson DG, Simon JC et al (1995) CD44 isoforms containing exon v3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 128:687–698
8. Borjesson PK, Postema EJ, Roos JC et al (2003) Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma. Clin Cancer Res 9(10 Pt 2):3961S–3972S
9. Borjesson PK, Jauw YW, Boellaard R et al (2006) Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 12(7 Pt 1):2133–2140. doi:10.1158/1078-0432.CCR-05-2137
10. Boyd DD, Kim SJ, Wang H, Jones TR, Gallick GE (2003) A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Am J Pathol 162(2):619–626. doi:10.1016/S0002-9440(10)63855-2
11. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):857–866. doi:10.1038/nrc1997
12. Casucci M, Nicolis di Robilant B, Falcone L et al (2013) CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122(20):3461–3472. doi:10.1182/blood-2013-04-493361
13. Chen CH, Cheng CY, Chen YC et al (2014) MicroRNA-328 inhibits renal tubular cell epithelial-to-mesenchymal transition by targeting the CD44 in pressure-induced renal fibrosis. PLoS One 9(6):e99802. doi:10.1371/journal.pone.0099802
14. Choi KY, Saravanakumar G, Park JH, Park K (2012) Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer. Coll Surf B Biointerfaces 99:82–94. doi:10.1016/j.colsurfb.2011.10.029
15. Colnot DR, Quak JJ, Roos JC et al (2000) Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 41(12):1999–2010
16. Colnot DR, Ossenkoppele GJ, Roos JC et al (2002) Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clin Cancer Res 8(11):3401–3406
17. Colnot DR, Roos JC, De Bree R et al (2003) Safety, biodistribution, pharmacokinetics, and immunogenicity of (99 m)Tc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 52:576–582
18. Cox JC, Ellington AD (2001) Automated selection of anti-protein aptamers. Bioorg Med Chem 9(10):2525–2531
19. Culty M, Nguyen HA, Underhill CB (1992) The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol 116(4):1055–1062
20. Culty M, Shizari M, Thompson EW, Underhill CB (1994) Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: correlation with invasive potential. J Cell Physiol 160(2):275–286
21. de Bree R, Roos JC, Quak JJ, den Hollander W, Snow GB, van Dongen GA (1995) Radioimmunoscintigraphy and biodistribution of technetium-99 m-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1(6):591–598
22. DeGrendele HC, Estess P, Picker LJ, Siegelman MH (1996) CD44 and its ligand hyaluronate mediate rolling under physiologic flow: a novel lymphocyte–endothelial cell primary adhesion pathway. J Exp Med 183(3):1119–1130
23. DeGrendele HC, Estess P, Siegelman MH (1997) Requirement for CD44 in activated T cell extravasation into an inflammatory site. Science 278(5338):672–675
24. Eliaz RE, Szoka FC Jr (2001) Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res 61(6):2592–2601
25. Eliaz RE, Nir S, Marty C, Szoka FC Jr (2004) Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res 64(2):711–718
26. Fortin MA, Salnikov AV, Nestor M, Heldin NE, Rubin K, Lundqvist H (2007) Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies. Eur J Nucl Med Mol Imaging 34(9):1376–1387. doi:10.1007/s00259-006-0346-5
27. Fuchs K, Hippe A, Schmaus A, Homey B, Sleeman JP, Orian-Rousseau V (2013) Opposing effects of high- and low-molecular weight hyaluronan on CXCL12-induced CXCR4 signaling depend on CD44. Cell Death Dis 4:e819. doi:10.1038/cddis.2013.364
28. Gately CL, Muul LM, Greenwood MA et al (1984) In vitro studies on the cell-mediated immune response to human brain tumors. II. Leukocyte-induced coats of glycosaminoglycan increase the resistance of glioma cells to cellular immune attack. J Immunol 133(6):3387–3395
29. Ghamande SA, Silverman MH, Huh W et al (2008) A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol 111(1):89–94. doi:10.1016/j.ygyno.2008.06.028
30. Ghatak S, Misra S, Toole BP (2002) Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 277(41):38013–38020. doi:10.1074/jbc.M202404200
31. Ghosh SC, Neslihan Alpay S, Klostergaard J (2012) CD44: a validated target for improved delivery of cancer therapeutics. Expert opinion on therapeutic targets 16(7):635–650. doi:10.1517/14728222.2012.687374
32. Goetinck PF, Stirpe NS, Tsonis PA, Carlone D (1987) The tandemly repeated sequences of cartilage link protein contain the sites for interaction with hyaluronic acid. J Cell Biol 105(5):2403–2408
33. Gold MA, Brady WE, Lankes HA et al (2012) A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 125(3):635–639. doi:10.1016/j.ygyno.2012.03.023
34. Goldstein LA, Zhou DF, Picker LJ et al (1989) A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell 56(6):1063–1072
35. Gunthert U, Hofmann M, Rudy W et al (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65(1):13–24. doi:10.1016/0092-8674(91)90403-L
36. Haylock AK, Spiegelberg D, Nilvebrant J, Sandstrom K, Nestor M (2014) In vivo characterization of the novel CD44v6-targeting Fab fragment AbD15179 for molecular imaging of squamous cell carcinoma: a dual-isotope study. EJNMMI Res 4(1):11. doi:10.1186/2191-219X-4-11
37. Heider KH, Sproll M, Susani S et al (1996) Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother 43(4):245–253
38. Henry JC, Park JK, Jiang J et al (2010) miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 403(1):120–125. doi:10.1016/j.bbrc.2010.10.130
39. Hermeking H (2010) The miR-34 family in cancer and apoptosis. Cell Death Differ 17(2):193–199. doi:10.1038/cdd.2009.56
40. Herrera MB, Bussolati B, Bruno S et al (2007) Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 72(4):430–441. doi:10.1038/sj.ki.5002334
41. Hibino S, Shibuya M, Engbring JA, Mochizuki M, Nomizu M, Kleinman HK (2004) Identification of an active site on the laminin alpha5 chain globular domain that binds to CD44 and inhibits malignancy. Cancer Res 64(14):4810–4816
42. Hofmann M, Rudy W, Zoller M et al (1991) CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 51(19):5292–5297
43. Iida J, Clancy R, Dorchak J et al (2014) DNA aptamers against exon v10 of CD44 inhibit breast cancer cell migration. PLoS ONE 9(2):e88712. doi:10.1371/journal.pone.0088712
44. Ishimoto T, Nagano O, Yae T et al (2011) CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19(3):387–400. doi:10.1016/j.ccr.2011.01.038
45. Jackson DG, Bell JI, Dickinson R, Timans J, Shields J, Whittle N (1995) Proteoglycan forms of the lymphocyte homing receptor CD44 are alternatively spliced variants containing the v3 exon. J Cell Biol 128(4):673–685
46. Jalkanen S, Bargatze RF, de los Toyos J, Butcher EC (1987) Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85–95 kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J Cell Biol 105:983–990
47. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12(10):1167–1174
48. Jung T, Castellana D, Klingbeil P et al (2009) CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia 11(10):1093–1105
49. Jung T, Gross W, Zoller M (2011) CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem 286(18):15862–15874. doi:10.1074/jbc.M110.208421
50. Knudson W, Biswas C, Toole BP (1984) Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis. Proc Natl Acad Sci U S A 81(21):6767–6771
51. Koppe M, Schaijk F, Roos J et al (2004) Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with early-stage breast cancer. Cancer Biother Radiopharm 19(6):720–729. doi:10.1089/cbr.2004.19.720
52. Laurent TC, Fraser JR (1992) Hyaluronan. Faseb J 6(7):2397–2404
53. Lesley J, Hyman R (1992) CD44 can be activated to function as an hyaluronic acid receptor in normal murine T cells. Eur J Immunol 22(10):2719–2723
54. Li C, Wu JJ, Hynes M et al (2011) c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 141(6):2218–2227. doi:10.1053/j.gastro.2011.08.009
55. Li L, Xie X, Luo J et al (2012) Targeted expression of miR-34a using the T-VISA system suppresses breast cancer cell growth and invasion. Mol Ther 20(12):2326–2334. doi:10.1038/mt.2012.201
56. Li L, Hao X, Qin J et al (2014) Antibody against CD44 s inhibits pancreatic tumor initiation and postradiation recurrence in mice. Gastroenterology 146(4):1108–1118. doi:10.1053/j.gastro.2013.12.035
57. Liu C, Kelnar K, Liu B et al (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17(2):211–215. doi:10.1038/nm.2284
58. Luo Y, Prestwich GD (1999) Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug Chem 10(5):755–763. doi:10.1021/bc9900338
59. Luo Y, Kirker KR, Prestwich GD (2000) Cross-linked hyaluronic acid hydrogel films: new biomaterials for drug delivery. J Control Release 69(1):169–184
60. Ma Q, Jiang Q, Pu Q et al (2013) MicroRNA-143 inhibits migration and invasion of human non-small-cell lung cancer and its relative mechanism. Int J Biol Sci 9(7):680–692. doi:10.7150/ijbs.6623
61. Matzke A, Herrlich P, Ponta H, Orian-Rousseau V (2005) A five-amino-acid peptide blocks Met- and Ron-dependent cell migration. Cancer Res 65(14):6105–6110. doi:10.1158/0008-5472.CAN-05-0207
62. McBride WH, Bard JB (1979) Hyaluronidase-sensitive halos around adherent cells. Their role in blocking lymphocyte-mediated cytolysis. J Exp Med 149(2):507–515
63. Mielgo A, van Driel M, Bloem A, Landmann L, Gunthert U (2005) A novel antiapoptotic mechanism based on interference of Fas signaling by CD44 variant isoforms. Cell Death Differ
64. Misra S, Hascall VC, De Giovanni C, Markwald RR, Ghatak S (2009) Delivery of CD44shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ mice. J Biol Chem. doi:10.1074/jbc.M806772200
65. Misra S, Heldin P, Hascall VC et al (2011) Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 278(9):1429–1443. doi:10.1111/j.1742-4658.2011.08071.x
66. Mizrahy S, Goldsmith M, Leviatan-Ben-Arye S et al (2014) Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. Nanoscale 6(7):3742–3752. doi:10.1039/c3nr06102g
67. Naor D, Sionov RV, Ish-Shalom D (1997) CD44: structure, function and association with the malignant process. In: VandeWoude GF, Klein G (eds) Advances in cancer research, vol 71. Elsevier, San-Diego, pp 243–318
68. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y (2002) CD44 in cancer. Crit Rev Clin Lab Sci 39(6):527–579
69. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA (2009) MicroRNAs—the micro steering wheel of tumour metastases. Nat Rev Cancer 9(4):293–302. doi:10.1038/nrc2619
70. O’Neill HC (1989) Antibody which defines a subset of bone marrow cells that can migrate to thymus. Immunology 68(1):59–65
71. Oppenheimer-Marks N, Davis LS, Lipsky PE (1990) Human T lymphocyte adhesion to endothelial cells and transendothelial migration. Alteration of receptor use relates to the activation status of both the T cell and the endothelial cell. J Immunol 145(1):140–148
72. Orian-Rousseau V (2010) CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46(7):1271–1277. doi:10.1016/j.ejca.2010.02.024
73. Orian-Rousseau V, Sleeman J (2014) CD44 is a multidomain signaling platform that integrates extracellular matrix cues with growth factor and cytokine signals. Adv Cancer Res 123:231–254. doi:10.1016/B978-0-12-800092-2.00009-5
74. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P, Ponta H (2002) CD44 is required for two consecutive steps in HGF/c-met signaling. Genes Dev 16(23):3074–3086
75. Orian-Rousseau V, Morrison H, Matzke A et al (2007) Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell 18(1):76–83
76. Pals ST, Hogervorst F, Keizer GD, Thepen T, Horst E, Figdor CC (1989) Identification of a widely distributed 90-kDa glycoprotein that is homologous to the Hermes-1 human lymphocyte homing receptor. J Immunol 143(3):851–857
77. Peach RJ, Hollenbaugh D, Stamenkovic I, Aruffo A (1993) Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol 122(1):257–264
78. Peer D, Margalit R (2004) Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer 108(5):780–789. doi:10.1002/ijc.11615
79. Peterson RM, Yu Q, Stamenkovic I, Toole BP (2000) Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites. Am J Pathol 156(6):2159–2167
80. Piotrowicz RS, Damaj BB, Hachicha M, Incardona F, Howell SB, Finlayson M (2011) A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. Mol Cancer Ther 10(11):2072–2082. doi:10.1158/1535-7163.MCT-11-0351
81. Ponta H, Sherman L, Herrlich PA (2003) CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4(1):33–45
82. Postema EJ, Borjesson PK, Buijs WC et al (2003) Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer. J Nucl Med 44(10):1690–1699
83. Pouyani T, Prestwich GD (1994) Functionalized derivatives of hyaluronic acid oligosaccharides: drug carriers and novel biomaterials. Bioconjug Chem 5(4):339–347
84. Qiu L, Li Z, Qiao M et al (2014) Self-assembled pH-responsive hyaluronic acid-g-poly[(l)-histidine] copolymer micelles for targeted intracellular delivery of doxorubicin. Acta Biomater 10(5):2024–2035. doi:10.1016/j.actbio.2013.12.025
85. Riechelmann H, Sauter A, Golze W et al (2008) Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 44(9):823–829. doi:10.1016/j.oraloncology.2007.10.009
86. Rudy W, Hofmann M, Schwartz-Albiez R et al (1993) The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res 53(6):1262–1268
87. 111In-labeled monoclonal antibody. Tumour Biol 29(3):137–144. doi:10.1159/000143399
88. Sandstrom K, Haylock AK, Spiegelberg D, Qvarnstrom F, Wester K, Nestor M (2012) A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio. Int J Oncol 40(5):1525–1532. doi:10.3892/ijo.2012.1352
89. Sauter A, Kloft C, Gronau S et al (2007) Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol 30(4):927–935
90. Schmitt M, Metzger M, Gradl D, Davidson G, Orian-Rousseau V (2014) CD44 functions in Wnt signaling by regulating LRP6 localization and activation. Cell Death Differ. doi:10.1038/cdd.2014.156
91. Schrijvers AH, Quak JJ, Uyterlinde AM et al (1993) MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 53(18):4383–4390
92. Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez-Rodriguez L, Minko T (2013) Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res 19(22):6193–6204. doi:10.1158/1078-0432.CCR-13-1536
93. Song S, Chen F, Qi H et al (2014a) Multifunctional tumor-targeting nanocarriers based on hyaluronic acid-mediated and pH-sensitive properties for efficient delivery of docetaxel. Pharm Res 31(4):1032–1045. doi:10.1007/s11095-013-1225-y
94. Song S, Qi H, Xu J et al (2014b) Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting. Pharm Res. doi:10.1007/s11095-014-1393-4
95. Sotiropoulou G, Pampalakis G, Lianidou E, Mourelatos Z (2009) Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell. RNA 15(8):1443–1461. doi:10.1261/rna.1534709
96. Straathof KC, Pule MA, Yotnda P et al (2005) An inducible caspase 9 safety switch for T-cell therapy. Blood 105(11):4247–4254. doi:10.1182/blood-2004-11-4564
97. Stroomer JW, Roos JC, Sproll M et al (2000) Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res 6(8):3046–3055
98. Sun S, Wang Z (2011) Head neck squamous cell carcinoma c-Met(+) cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int J Cancer 129(10):2337–2348. doi:10.1002/ijc.25927
99. Tijink BM, Buter J, de Bree R et al (2006) A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 12(20 Pt 1):6064–6072
100. Todaro M, Gaggianesi M, Catalano V et al (2014) CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14(3):342–356. doi:10.1016/j.stem.2014.01.009
101. Trapasso S, Allegra E (2012) Role of CD44 as a marker of cancer stem cells in head and neck cancer. Biologics 6:379–383. doi:10.2147/BTT.S37906
102. Tremmel M, Matzke A, Albrecht I et al (2009) A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood 114(25):5236–5244. doi:10.1182/blood-2009-04-219204
103. Turley EA, Tretiak M (1985) Glycosaminoglycan production by murine melanoma variants in vivo and in vitro. Cancer Res 45(10):5098–5105
104. Ugarte-Berzal E, Bailon E, Amigo-Jimenez I et al (2012) A 17-residue sequence from the matrix metalloproteinase-9 (MMP-9) hemopexin domain binds alpha4beta1 integrin and inhibits MMP-9-induced functions in chronic lymphocytic leukemia B cells. J Biol Chem 287(33):27601–27613. doi:10.1074/jbc.M112.354670
105. Ugarte-Berzal E, Bailon E, Amigo-Jimenez I, Albar JP, Garcia-Marco JA, Garcia-Pardo A (2014) A novel CD44-binding peptide from the pro-matrix metalloproteinase-9 hemopexin domain impairs adhesion and migration of chronic lymphocytic leukemia (CLL) cells. J Biol Chem 289(22):15340–15349. doi:10.1074/jbc.M114.559187
106. Valentine A, O’Rourke M, Yakkundi A et al (2011) FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. Clin Cancer Res 17(5):1044–1056. doi:10.1158/1078-0432.CCR-10-2241
107. Van Hal NL, Van Dongen GA, Rood-Knippels EM, Van Der Valk P, Snow GB, Brakenhoff RH (1996) Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. Int J Cancer 68(4):520–527
108. Van Hal NL, Van Dongen GA, Ten Brink CB, Herron JN, Snow GB, Brakenhoff RH (1997) Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope. Cancer Immunol Immunother 45(2):88–92
109. Ventura A, Jacks T (2009) MicroRNAs and cancer: short RNAs go a long way. Cell 136(4):586–591. doi:10.1016/j.cell.2009.02.005
110. Verel I, Heider KH, Siegmund M et al (2002) Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int J Cancer 99(3):396–402
111. Vermeulen JF, van Brussel AS, Adams A et al (2013) Near-infrared fluorescence molecular imaging of ductal carcinoma in situ with CD44v6-specific antibodies in mice: a preclinical study. Mol Imaging Biol 15(3):290–298. doi:10.1007/s11307-012-0605-8
112. Vugts DJ, Heuveling DA, Stigter-van Walsum M et al (2014) Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: prelude to Phase 1 clinical studies. MAbs 6(2):567–575. doi:10.4161/mabs.27415
113. Weigand S, Herting F, Maisel D et al (2012) Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist. Cancer Res 72(17):4329–4339. doi:10.1158/0008-5472.CAN-12-0136
114. Williams K, Motiani K, Giridhar PV, Kasper S (2013) CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med 238(3):324–338. doi:10.1177/1535370213480714
115. Woodward WA, Sulman EP (2008) Cancer stem cells: markers or biomarkers? Cancer Metastasis Rev 27(3):459–470. doi:10.1007/s10555-008-9130-2
116. Xu XM, Chen Y, Chen J et al (2003) A peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis. Cancer Res 63(18):5685–5690
117. Yadav AK, Mishra P, Jain S, Mishra AK, Agrawal GP (2008) Preparation and characterization of HA–PEG–PCL intelligent core-corona nanoparticles for delivery of doxorubicin. J Drug Target 16(6):464–478. doi:10.1080/10611860802095494
118. Yang B, Yang BL, Savani RC, Turley EA (1994) Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein. EMBO J 13(2):286–296
119. Yu Q, Stamenkovic I (1999) Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 13(1):35–48
120. Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14(2):163–176
121. Yu Q, Stamenkovic I (2004) Transforming growth factor-beta facilitates breast carcinoma metastasis by promoting tumor cell survival. Clin Exp Metastasis 21(3):235–242
122. Yu Q, Toole BP, Stamenkovic I (1997) Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med 186(12):1985–1996
123. Yu WH, Woessner JF Jr, McNeish JD, Stamenkovic I (2002) CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16(3):307–323
124. Zeilstra J, Joosten SP, Dokter M, Verwiel E, Spaargaren M, Pals ST (2008) Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. Cancer Res 68(10):3655–3661
125. Zeilstra J, Joosten SP, van Andel H et al (2014) Stem cell CD44v isoforms promote intestinal cancer formation in apc(min) mice downstream of wnt signaling. Oncogene 33(5):665–670. doi:10.1038/onc.2012.611
126. Zhang L, Underhill CB, Chen L (1995) Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res 55(2):428–433
127. Zhang S, Wu CC, Fecteau JF et al (2013) Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad 110(15):6127–6132. doi:10.1073/pnas.1221841110